Therapeutic Potential of GLP-1 Receptor Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical Implications

被引:0
|
作者
Zhang, Xinyu [1 ,2 ,3 ]
Cao, Chao [1 ,2 ]
Zheng, Fei [1 ,2 ]
Liu, Chang [1 ,2 ]
Tian, Xiuqing [1 ,2 ,3 ]
机构
[1] Shandong First Med Univ, Affiliated Hosp 1, Dept Cardiol, 16766 Jingshi Rd, Jinan City 250014, Peoples R China
[2] Shandong Prov Qianfoshan Hosp, 16766 Jingshi Rd, Jinan City 250014, Peoples R China
[3] Shandong First Med Univ & Shandong Acad Med Sci, 6699 Qingdao Rd, Jinan City 250117, Peoples R China
关键词
GLP-1; RAs; Cardiovascular; Type; 2; diabetes; Ischemic cardiomyopathy; Diabetic cardiomyopathy; Heart failure; GLUCAGON-LIKE PEPTIDE-1; PANCREATIC BETA-CELL; IMPROVING MITOCHONDRIAL-FUNCTION; LEFT-VENTRICULAR PERFORMANCE; ACUTE MYOCARDIAL-INFARCTION; HEART-FAILURE; INSULIN-SECRETION; EJECTION FRACTION; CONSCIOUS DOGS; BLOOD-PRESSURE;
D O I
10.1007/s10557-025-07670-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundGlucagon-like peptide-1 (GLP-1) is a crucial incretin hormone secreted by intestinal endocrine L cells. Given its pivotal physiological role, researchers have developed GLP-1 receptor agonists (GLP-1 RAs) through structural modifications. These analogues display pharmacological effects similar to those of GLP-1 but with augmented stability and are regarded as an effective means of regulating blood glucose levels in clinical practice.ObjectiveThis review aims to comprehensively summarize the role of GLP-1 RAs in the management of diabetes mellitus (DM) and cardiovascular disease (CVD), with a particular emphasis on the underlying signal transduction pathways and their therapeutic potential.MethodsA comprehensive review was carried out through literature research.Results and DiscussionIn pancreatic beta-cells, GLP-1 RAs regulate the secretion of insulin and glucagon in a glucosedependent manner by influencing signaling pathways such as cAMP, PI3K, and MAPK. They also contribute to the regulation of blood glucose levels by promoting the proliferation of beta-cells and inhibiting apoptosis in these cells. Recent comprehensive studies have also demonstrated the favorable impact of GLP-1 RAs on cardiovascular wellbeing. In addition to the cardiovascular protection afforded by glucose metabolism regulation, a large body of evidence from animal and cellular studies has corroborated the beneficial effects of GLP-1 RAs on conditions such as heart failure (HF), hypertension, and ischemic cardiomyopathy. These benefits are mainly attributed to the alleviation of inflammatory responses, reduction of oxidative stress, and prevention of cell apoptosis. Clinical data shows that GLP-1 RAs can reduce the risk of major adverse cardiovascular events (MACE) in diabetic patients.ConclusionGLP-1 RAs play an important role in the management of both diabetes and cardiovascular diseases. They show potential therapeutic value through the modulation of multiple signal transduction pathways. However, there may still be some issues in practical applications that require further research and resolution.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] GLP-1 Receptor Agonists in Diabetic Kidney Disease
    Michos, Erin D.
    Tuttle, Katherine R.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 16 (10): : 1578 - 1580
  • [43] GLP-1 receptor agonists for Parkinson's disease
    Mulvaney, Caroline A.
    Duarte, Goncalo S.
    Handley, Joel
    Evans, David J. W.
    Menon, Suresh
    Wyse, Richard
    Emsley, Hedley C. A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (07):
  • [44] Pharmacology of GLP-1 Agonists: Describing the Therapeutic Potential to Patients
    Spellman, Craig W.
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2011, 111 (02): : ES10 - ES14
  • [45] The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes
    Thomas, Merlin C.
    DIABETES & METABOLISM, 2017, 43 : 2S20 - 2S27
  • [46] Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
    Ostergaard, L.
    Frandsen, Christian S.
    Madsbad, S.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (02) : 241 - 265
  • [47] Potential implications of long-acting GLP-1 receptor agonists for critically ill
    Wang, Luping
    Yang, Hao
    Xia, Xiaoxiao
    Wang, Bo
    Wu, Qin
    CRITICAL CARE, 2024, 28 (01)
  • [48] GLP-1 receptor agonists and cardiovascular disease: drug-specific or class effects?
    Zweck, Elric
    Roden, Michael
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (02): : 89 - 90
  • [49] GLP-1 Receptor Agonists Improve Cardiovascular Outcomes in Patients With Celiac Disease and Obesity
    Nieto, Luis
    Narvaez, Sharon
    Shepherd, Katherine
    Adeniran, Olanrewaju
    Vega, Kenneth
    Haggerty, Treah
    Davisson, Laura
    OBESITY, 2024, 32 : 87 - 88
  • [50] Effects of GLP-1 receptor agonists on neurological complications of diabetes
    Garcia-Casares, Natalia
    Gonzalez-Gonzalez, Guillermo
    de la Cruz-Cosme, Carlos
    Garzon-Maldonado, Francisco J.
    de Rojas-Leal, Carmen
    Ariza, Maria J.
    Narvaez, Manuel
    Barbancho, Miguel Angel
    Garcia-Arnes, Juan Antonio
    Tinahones, Francisco J.
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2023, 24 (04): : 655 - 672